
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8685598/publications.pdf Version: 2024-02-01



KIDII TODKOV

#	Article	IF	CITATIONS
1	Eosinophilic vacuolated tumor (EVT) of kidney demonstrates sporadic TSC/MTOR mutations: next-generation sequencing multi-institutional study of 19 cases. Modern Pathology, 2022, 35, 344-351.	5.5	40
2	Recurrent KRAS mutations are early events in the development of papillary renal neoplasm with reverse polarity. Modern Pathology, 2022, 35, 1279-1286.	5.5	17
3	ABCC2 expression in papillary renal cell carcinoma provides better prognostic stratification than WHO/ISUP nucleolar grade. Human Pathology, 2022, 120, 57-70.	2.0	3
4	Do we need an updated classification of oncocytic renal tumors?. Modern Pathology, 2022, 35, 1140-1150.	5.5	16
5	Expanding the clinicopathological spectrum of succinate dehydrogenase-deficient renal cell carcinoma with a focus on variant morphologies: a study of 62 new tumors in 59 patients. Modern Pathology, 2022, 35, 836-849.	5.5	20
6	Low-grade oncocytic tumor (LOT) - a new renal entity ready for a prime time: An updated review Histology and Histopathology, 2022, , 18435.	0.7	4
7	p53 null phenotype is a "positive result―in urothelial carcinoma in situ. Modern Pathology, 2022, 35, 1287-1292.	5.5	5
8	The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. Archives of Pathology and Laboratory Medicine, 2021, 145, 461-493.	2.5	143
9	Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 295.e1-295.e8.	1.6	6
10	Comprehensive Review of Numerical Chromosomal Aberrations in Chromophobe Renal Cell Carcinoma Including Its Variant Morphologies. Advances in Anatomic Pathology, 2021, 28, 8-20.	4.3	14
11	Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Modern Pathology, 2021, 34, 1167-1184.	5.5	118
12	New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Modern Pathology, 2021, 34, 1392-1424.	5.5	138
13	The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers. Advances in Anatomic Pathology, 2021, 28, 196-208.	4.3	20
14	The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia. Advances in Anatomic Pathology, 2021, 28, 179-195.	4.3	23
15	Primary Follicular Dendritic Cell Sarcoma of Urinary Bladder. International Journal of Surgical Pathology, 2021, , 106689692098162.	0.8	0
16	Undifferentiated and dedifferentiated urological carcinomas: lessons learned from the recent developments. Seminars in Diagnostic Pathology, 2021, 38, 152-162.	1.5	3
17	Diagnosis of "cribriform" prostatic adenocarcinoma: an interobserver reproducibility study among urologic pathologists with recommendations. American Journal of Cancer Research, 2021, 11, 3990-4001.	1.4	4
18	ESC, ALK, HOT and LOT: Three Letter Acronyms of Emerging Renal Entities Knocking on the Door of the WHO Classification. Cancers, 2020, 12, 168.	3.7	54

#	Article	IF	CITATIONS
19	"Renal Cell Carcinoma With Leiomyomatous Stroma―Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity. American Journal of Surgical Pathology, 2020, 44, 571-581.	3.7	67
20	Expanding the morphologic spectrum of chromophobe renal cell carcinoma: A study of 8 cases with papillary architecture. Annals of Diagnostic Pathology, 2020, 44, 151448.	1.3	25
21	Reporting Practices and Resource Utilization in the Era of Intraductal Carcinoma of the Prostate. American Journal of Surgical Pathology, 2020, 44, 673-680.	3.7	31
22	Molecular Genetic Features of Primary Nonurachal Enteric-type Adenocarcinoma, Urachal Adenocarcinoma, Mucinous Adenocarcinoma, and Intestinal Metaplasia/Adenoma: Review of the Literature and Next-generation Sequencing Study. Advances in Anatomic Pathology, 2020, 27, 303-310.	4.3	10
23	PTEN Loss in a Prostate Cancer Cohort From Jordan. Applied Immunohistochemistry and Molecular Morphology, 2020, 28, 389-394.	1.2	6
24	ALK rearranged renal cell carcinoma (ALK-RCC): a multi-institutional study of twelve cases with identification of novel partner genes CLIP1, KIF5B and KIAA1217. Modern Pathology, 2020, 33, 2564-2579.	5.5	49
25	Doxycyclineâ€induced spongiotic oesophagitis is associated with eosinophilic vascular degeneration. Histopathology, 2020, 77, 684-686.	2.9	2
26	Gene fusion characterisation of rare aggressive prostate cancer variants—adenosquamous carcinoma, pleomorphic giantâ€cell carcinoma, and sarcomatoid carcinoma: an analysis of 19 cases. Histopathology, 2020, 77, 890-899.	2.9	15
27	In Situ Metabolomics Expands the Spectrum of Renal Tumours Positive on 99mTc-sestamibi Single Photon Emission Computed Tomography/Computed Tomography Examination. European Urology Open Science, 2020, 22, 88-96.	0.4	6
28	<prg and="" biopsies="" cancer="" expression="" high-grade="" in="" intraepithelial<br="" prostate="" prostatic="" with="" without="">neoplasia: a study in Jordanian Arab patients. Research and Reports in Urology, 2019, Volume 11, 149-155.</prg>	1.0	0
29	Primary adenocarcinoma of bulbomembranous urethra: An exceedingly rare carcinoma in a male patient. Urology Case Reports, 2019, 26, 100941.	0.3	1
30	<changes at="" in="" of="" patients="" prostatectomy="" radical="" risk-group="" stratification="" the<br="" undergoing="">Southern Alberta Institute of Urology over time. Research and Reports in Urology, 2019, Volume 11, 69-75.</changes>	1.0	1
31	Dataset for the reporting of prostate carcinoma in radical prostatectomy specimens: updated recommendations from the International Collaboration on Cancer Reporting. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 263-277.	2.8	19
32	Highâ€grade oncocytic tumour (HOT) of kidney in a patient with tuberous sclerosis complex. Histopathology, 2019, 75, 440-442.	2.9	41
33	Lowâ€grade oncocytic tumour of kidney (CD117â€negative, cytokeratin 7â€positive): a distinct entity?. Histopathology, 2019, 75, 174-184.	2.9	100
34	The effect of time from biopsy to radical prostatectomy on adverse pathologic outcomes. Research and Reports in Urology, 2019, Volume 11, 53-60.	1.0	11
35	New and emerging renal entities: a perspective postâ€< scp>WHO 2016 classification. Histopathology, 2019, 74, 31-59.	2.9	107
36	Immunohistochemical screening for the diagnosis of succinate dehydrogenase-deficient renal cell carcinoma and fumarate hydratase-deficient renal cell carcinoma. Annals of Translational Medicine, 2019, 7, S324-S324.	1.7	5

#	Article	IF	CITATIONS
37	Dataset for the reporting of prostate carcinoma in core needle biopsy and transurethral resection and enucleation specimens: recommendations from the International Collaboration on Cancer Reporting (ICCR). Pathology, 2019, 51, 11-20.	0.6	19
38	Fumarate hydratase deficient renal cell carcinoma and fumarate hydratase deficient-like renal cell carcinoma: Morphologic comparative study of 23 genetically tested cases. Ceskoslovenska Patologie, 2019, 55, 244-249.	0.1	2
39	Papillary renal cell carcinoma with cytologic and molecular genetic features overlapping with renal oncocytoma: Analysis of 10 cases. Annals of Diagnostic Pathology, 2018, 35, 1-6.	1.3	15
40	Eosinophilic Solid and Cystic Renal Cell Carcinoma: Imaging Features of a Novel Neoplasm. Urology, 2018, 114, e9-e10.	1.0	10
41	Eosinophilic solid and cystic renal cell carcinomas have metastatic potential. Histopathology, 2018, 72, 1066-1067.	2.9	49
42	Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase–deficient Renal Cell Carcinoma. American Journal of Surgical Pathology, 2018, 42, 279-292.	3.7	101
43	Benign mimics of prostatic adenocarcinoma. Modern Pathology, 2018, 31, 22-46.	5.5	15
44	SWI/SNF protein expression status in fumarate hydratase–deficient renal cell carcinoma: immunohistochemical analysis of 32 tumors from 28 patients. Human Pathology, 2018, 77, 139-146.	2.0	18
45	Stromal lipofuscinosis of the seminal vesicle: Incidental finding in two patients treated for prostatic adenocarcinoma by prostatectomy and cryotherapy. Human Pathology: Case Reports, 2018, 11, 21-24.	0.2	1
46	Biphasic papillary renal cell carcinoma is a rare morphological variant with frequent multifocality: a study of 28 cases. Histopathology, 2018, 72, 777-785.	2.9	31
47	VSTM2A Overexpression Is a Sensitive and Specific Biomarker for Mucinous Tubular and Spindle Cell Carcinoma (MTSCC) of the Kidney. American Journal of Surgical Pathology, 2018, 42, 1571-1584.	3.7	34
48	Concordance of "Case Level―Global, Highest, and Largest Volume Cancer Grade Group on Needle Biopsy Versus Grade Group on Radical Prostatectomy. American Journal of Surgical Pathology, 2018, 42, 1522-1529.	3.7	23
49	"High-grade oncocytic renal tumor†morphologic, immunohistochemical, and molecular genetic study of 14 cases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 725-738.	2.8	83
50	Prognostic pathological factors in radical cystectomy after neoadjuvant chemotherapy. Histopathology, 2018, 73, 732-740.	2.9	15
51	Somatic Bi-allelic Loss of TSC Genes in Eosinophilic Solid and Cystic Renal Cell Carcinoma. European Urology, 2018, 74, 483-486.	1.9	86
52	Renal cell carcinoma morphologically similar to fumarate hydrataseâ€deficient RCC in a patient with BRCA2 germline mutation. Pathology International, 2018, 68, 541-542.	1.3	5
53	Challenges in Pathologic Staging of Renal Cell Carcinoma. American Journal of Surgical Pathology, 2018, 42, 1253-1261.	3.7	22
54	Gleason score assignment is the sole responsibility of the pathologist. Histopathology, 2018, 73, 5-7.	2.9	12

#	Article	IF	CITATIONS
55	Global Gleason grade groups in prostate cancer: concordance of biopsy and radical prostatectomy grades and predictors of upgrade and downgrade. Histopathology, 2017, 70, 1098-1106.	2.9	42
56	Programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) expression in fumarate hydratase-deficient renal cell carcinoma. Annals of Diagnostic Pathology, 2017, 29, 17-22.	1.3	29
57	Prostate cancer in Jordanian-Arab population: ERG status and relationship with clinicopathologic characteristics. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 753-759.	2.8	8
58	Diagnostic criteria for oncocytic renal neoplasms: a survey of urologic pathologists. Human Pathology, 2017, 63, 149-156.	2.0	89
59	Do significant TFE3 gene rearrangements occur in succinate dehydrogenase-deficient renal cell carcinoma? Borderline FISH results should be interpreted with caution. Modern Pathology, 2017, 30, 1507-1508.	5.5	6
60	Eosinophilic Solid and Cystic Renal Cell Carcinoma (ESC RCC). American Journal of Surgical Pathology, 2017, 41, 1299-1308.	3.7	107
61	Small cell-like glandular proliferation of prostate: a rare lesion not related to small cell prostate cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 47-54.	2.8	7
62	Cystic Renal Oncocytoma and Tubulocystic Renal Cell Carcinoma. Applied Immunohistochemistry and Molecular Morphology, 2016, 24, 112-119.	1.2	18
63	Eosinophilic, Solid, and Cystic Renal Cell Carcinoma. American Journal of Surgical Pathology, 2016, 40, 60-71.	3.7	139
64	Fumarate Hydratase–deficient Uterine Leiomyomas Occur in Both the Syndromic and Sporadic Settings. American Journal of Surgical Pathology, 2016, 40, 599-607.	3.7	102
65	NLRP3 Localizes to the Tubular Epithelium in Human Kidney and Correlates With Outcome in IgA Nephropathy. Scientific Reports, 2016, 6, 24667.	3.3	55
66	What is new in Genitourinary Pathology? Recent developments and highlights of the new 2016 World Health Organization classification of tumors of the urinary system and male genital organs. Applied Cancer Research, 2016, 36, .	1.0	8
67	Malakoplakia associated with prostatic adenocarcinoma. Annals of Diagnostic Pathology, 2016, 22, 33-37.	1.3	22
68	Fumarate Hydratase–deficient Renal Cell Carcinoma Is Strongly Correlated With Fumarate Hydratase Mutation and Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome. American Journal of Surgical Pathology, 2016, 40, 865-875.	3.7	182
69	Biallelic Alteration and Dysregulation of the Hippo Pathway in Mucinous Tubular and Spindle Cell Carcinoma of the Kidney. Cancer Discovery, 2016, 6, 1258-1266.	9.4	66
70	Tubulocystic Carcinoma of the Kidney With Poorly Differentiated Foci. American Journal of Surgical Pathology, 2016, 40, 1457-1472.	3.7	112
71	Solid papillary renal cell carcinoma: clinicopathologic, morphologic, and immunohistochemical analysis of 10 cases and review of the literature. Annals of Diagnostic Pathology, 2016, 23, 51-57.	1.3	19
72	ERG Expression in Prostate Needle Biopsy. Applied Immunohistochemistry and Molecular Morphology, 2015, 23, 499-505.	1.2	19

#	Article	IF	CITATIONS
73	Long-term outcome of primary Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP) including PUNLMP with inverted growth. Diagnostic Pathology, 2015, 10, 3.	2.0	27
74	Diagnosis of Gleason Pattern 5 Prostate Adenocarcinoma on Core Needle Biopsy. American Journal of Surgical Pathology, 2015, 39, 1242-1249.	3.7	43
75	Diagnosis of "Poorly Formed Glands―Gleason Pattern 4 Prostatic Adenocarcinoma on Needle Biopsy. American Journal of Surgical Pathology, 2015, 39, 1331-1339.	3.7	67
76	Urinary bladder xanthoma: a multiâ€institutional series of 17 cases. Histopathology, 2015, 67, 255-261.	2.9	7
77	Handling and reporting of orchidectomy specimens with testicular cancer: areas of consensus and variation among 25 experts and 225 European pathologists. Histopathology, 2015, 67, 313-324.	2.9	41
78	Renal Leiomyoma. American Journal of Surgical Pathology, 2015, 39, 349-356.	3.7	29
79	Mixed Epithelial-Stromal Tumor (MEST) of Seminal Vesicle. Advances in Anatomic Pathology, 2015, 22, 113-120.	4.3	35
80	Contemporary Gleason Grading System. , 2015, , 13-32.		3
81	Upper Urinary Tract Urothelial Carcinoma Pathology. , 2015, , 45-89.		0
82	Prostate cancer after initial high-grade prostatic intraepithelial neoplasia and benign prostate biopsy. Canadian Journal of Urology, 2015, 22, 8056-62.	0.0	9
83	Diagnostic criteria for ductal adenocarcinoma of the prostate: interobserver variability among 20 expert uropathologists. Histopathology, 2014, 65, 216-227.	2.9	40
84	Best Practices Recommendations in the Application of Immunohistochemistry in the Bladder Lesions. American Journal of Surgical Pathology, 2014, 38, e20-e34.	3.7	155
85	Best Practices Recommendations in the Application of Immunohistochemistry in Urologic Pathology. American Journal of Surgical Pathology, 2014, 38, 1017-1022.	3.7	155
86	Succinate Dehydrogenase (SDH)-deficient Renal Carcinoma. American Journal of Surgical Pathology, 2014, 38, 1588-1602.	3.7	282
87	Tuberous Sclerosis–associated Renal Cell Carcinoma. American Journal of Surgical Pathology, 2014, 38, 1457-1467.	3.7	211
88	Perineural Invasion in Prostate Cancer Patients Who Are Potential Candidates for Active Surveillance: Validation Study. Urology, 2014, 84, 149-152.	1.0	17
89	Inflammasome-Independent NLRP3 Augments TGF-β Signaling in Kidney Epithelium. Journal of Immunology, 2013, 190, 1239-1249.	0.8	202
90	Long-term Clinical Outcome of Inverted Urothelial Papilloma Including Cases With Focal Papillary Pattern: Is Continuous Surveillance Necessary?. Urology, 2013, 82, 857-860.	1.0	19

#	Article	IF	CITATIONS
91	ERG Protein Expression and Gene Rearrangements Are Present at Lower Rates in Metastatic and Locally Advanced Castration-resistant Prostate Cancer Compared to Localized Disease. Urology, 2013, 82, 394-399.	1.0	22
92	Dataset for reporting of prostate carcinoma in radical prostatectomy specimens: recommendations from the International Collaboration on Cancer Reporting. Histopathology, 2013, 62, 203-218.	2.9	32
93	Testicular hilum and vascular invasion predict advanced clinical stage in nonseminomatous germ cell tumors. Modern Pathology, 2013, 26, 579-586.	5.5	64
94	Handling and Staging of Renal Cell Carcinoma. American Journal of Surgical Pathology, 2013, 37, 1505-1517.	3.7	118
95	Interobserver agreement for Polyomavirus nephropathy grading in renal allografts using the working proposal from the 10th Banff Conference on Allograft Pathology. Human Pathology, 2011, 42, 2018-2024.	2.0	53
96	Mesothelioma of tunica vaginalis of "uncertain malignant potential" - an evolving concept: case report and review of the literature. Diagnostic Pathology, 2011, 6, 78.	2.0	27
97	Re: Rodolfo Montironi, Liang Cheng, Antonio Lopez-Beltran, et al. Original Gleason System Versus 2005 ISUP Modified Gleason System: The Importance of Indicating Which System Is Used in the Patient's Pathology and Clinical Reports. Eur Urol 2010;58:369–73. European Urology, 2011, 59, e5-e6.	1.9	1
98	Detection ofERGgene rearrangements andPTENdeletions in unsuspected prostate cancer of the transition zone. Cancer Biology and Therapy, 2011, 11, 562-566.	3.4	35
99	Progression From High-Grade Prostatic Intraepithelial Neoplasia to Cancer: A Randomized Trial of Combination Vitamin-E, Soy, and Selenium. Journal of Clinical Oncology, 2011, 29, 2386-2390.	1.6	70
100	A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer. Cancer, 2010, 116, 323-330.	4.1	136
101	Renal oncocytoma revisited: a clinicopathological study of 109 cases with emphasis on problematic diagnostic features. Histopathology, 2010, 57, 893-906.	2.9	98
102	â€~Insignificant' prostate cancer on prostatectomy and cystoprostatectomy: variation on a theme â€~lowâ€volume/ lowâ€grade' prostate cancer?. BJU International, 2010, 106, 304-315.	2.5	18
103	The NLRP3 Inflammasome Promotes Renal Inflammation and Contributes to CKD. Journal of the American Society of Nephrology: JASN, 2010, 21, 1732-1744.	6.1	456
104	TMPRSS2-ERG gene fusion in transition zone prostate cancer. Modern Pathology, 2010, 23, 1040-1041.	5.5	11
105	Oncolytic Viral Therapy for Prostate Cancer: Efficacy of Reovirus as a Biological Therapeutic. Cancer Research, 2010, 70, 2435-2444.	0.9	83
106	Referral and treatment rates of neoadjuvant chemotherapy in muscle-invasive bladder cancer before and after publication of a clinical practice guideline. Canadian Urological Association Journal, 2010, 4, 263-267.	0.6	42
107	Usefulness of Cytokeratin 5/6 and AMACR Applied as Double Sequential Immunostains for Diagnostic Assessment of Problematic Prostate Specimens. American Journal of Clinical Pathology, 2009, 132, 211-220.	0.7	27
108	A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer. Cancer, 2009, 115, 4695-4704.	4.1	49

#	Article	IF	CITATIONS
109	The impact of the 2005 International Society of Urological Pathology (ISUP) consensus on Gleason grading in contemporary practice. Histopathology, 2009, 55, 384-391.	2.9	60
110	Arias-Stella reaction as a diagnostic pitfall in a bladder biopsy with endometriosis: Case report and review of the pseudoneoplastic bladder lesions. Pathology Research and Practice, 2009, 205, 653-656.	2.3	10
111	Prostate Cancer With Tertiary Gleason Pattern 5 in Prostate Needle Biopsy. American Journal of Surgical Pathology, 2009, 33, 233-240.	3.7	39
112	Interobserver Variability Between Expert Urologic Pathologists for Extraprostatic Extension and Surgical Margin Status in Radical Prostatectomy Specimens. American Journal of Surgical Pathology, 2008, 32, 1503-1512.	3.7	123
113	How Much Tissue Sampling Is Required When Unsuspected Minimal Prostate Carcinoma Is Identified on Transurethral Resection?. Archives of Pathology and Laboratory Medicine, 2008, 132, 1313-1316.	2.5	21
114	A nomogram for predicting lowâ€volume/lowâ€grade prostate cancer. Cancer, 2007, 110, 2441-2447.	4.1	64
115	Editorial Comment on: Systematic Assessment of the Ability of the Number and Percentage of Positive Biopsy Cores to Predict Pathologic Stage and Biochemical Recurrence after Radical Prostatectomy. European Urology, 2007, 52, 743-744.	1.9	2
116	Epithelioid angiosarcoma of the bladder after irradiation for endometrioid adenocarcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 450, 245-246.	2.8	23
117	No Residual Cancer on Radical Prostatectomy After Positive 10-Core Biopsy: Incidence, Biopsy Findings, and DNA Specimen Identity Analysis. Archives of Pathology and Laboratory Medicine, 2006, 130, 811-816.	2.5	30
118	Use Of Digital Maps and Sampling of Radical Prostatectomy Specimens. Archives of Pathology and Laboratory Medicine, 2006, 130, 1751-1752.	2.5	3
119	Variation in meiotic recombination frequencies among human males. Human Genetics, 2005, 116, 172-178.	3.8	73
120	Discontinuities and unsynapsed regions in meiotic chromosomes have a cis effect on meiotic recombination patterns in normal human males. Human Molecular Genetics, 2005, 14, 3013-3018.	2.9	27
121	HPC2/ELAC2 gene variants associated with incident prostate cancer. Journal of Human Genetics, 2003, 48, 634-638.	2.3	14
122	Antibody-Mediated Rejection Criteria - an Addition to the Banff '97 Classification of Renal Allograft Rejection. American Journal of Transplantation, 2003, 3, 708-714.	4.7	960
123	Reproducibility of the Banff schema in reporting protocol biopsies of stable renal allografts. Nephrology Dialysis Transplantation, 2002, 17, 1081-1084.	0.7	67
124	The Banff 97 working classification of renal allograft pathology. Kidney International, 1999, 55, 713-723.	5.2	2,817
125	Kidney allograft with a lymphocytic infiltrate: Acute rejection, posttransplantation lymphoproliferative disorder, neither, or both entities?. American Journal of Kidney Diseases, 1997, 30, 449-454.	1.9	25